Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: Cost-utility analysis using a Markov model

PharmacoEconomics

Volumn 26, Issue 4, 2008, Pages 311-328

  Kreck, Simon ^a   Klaus, Jochen ^b   Leidl, Reiner ^c   Von Tirpitz, Christian ^b   Konnopka, Alexander ^a   Matschinger, Herbert ^a   König, Hans Helmut ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Calcium colecalciferol, therapeutic use; Cost utility; Fracture, prevention; Ibandronic acid, therapeutic use; Inflammatory bowel disease, contributory factors; Osteoporosis, treatment; Sodium fluoride colecalciferol, therapeutic use

Indexed keywords

CITRATE CALCIUM; COLECALCIFEROL; FLUORIDE SODIUM; IBANDRONIC ACID;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ENTERITIS; FRAGILITY FRACTURE; GERMANY; HEALTH CARE COST; HUMAN; MONTE CARLO METHOD; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

EID: 41449094124     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826040-00004     Document Type: Article

References (59)

1. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40 (2): 228-33
2. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10 (2): 250-6
3. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5 (3): 156-60
4. Von Tirpitz C, Pischulti G, Klaus J, et al. Pathological bone density in chronic inflammatory bowel diseases: prevalence and risk factors [in German]. Z Gastroenterol 1999; 37 (1): 5-12
5. Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung e.V. (DCCV) [online]. Available at URL: http://www.dccv.de/ [Accessed 2006 Jan 15]
6. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51 (5): 654-8
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348 (9041): 1535-41
8. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344 (5): 333-40
9. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19 (8): 1241-9
10. Borgstrom F, Johnell O, Jonsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004; 34 (6): 1064-71
11. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005; 16 (1): 15-25
12. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004; 15 (11): 862-71
13. Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21 (5): 305-14
14. Semeao EJ, Stallings VA, Peck SN, et al. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112 (5): 1710-3
15. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46 (2): 176-81
16. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312 (7041): 1254-9
17. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004; 20 (3): 341-9
18. De Laet CE, van Hout BA, Burger H, et al. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997; 315 (7102): 221-5
19. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17 (1): 1-10
20. The European Prospective Osteoporosis Study (EPOS) Group. The relationship between bone density and incident vertebral fracture in men and women. J Bone Miner Res 2002; 17 (12): 2214-21
21. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004; 34 (4): 599-604
22. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14 (5): 821-8
23. Arden NK, Cooper C. Assessment of the risk of fracture in patients with gastrointestinal disease. Eur J Gastroenterol Hepatol 2003; 15 (8): 865-8
24. von Tirpitz C, Klaus J, Hoffmann J, et al. Treatment of osteoporosis in Crohn's disease: final data of a multcenter 3.5-years study comparing sodium fluoride, ibandronate and substitution of calcium and vitamin D. Gastroenterology 2005; 128 (4 Suppl. 2): A588
25. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20 (7): 1185-94
26. De Laet CE, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 13 (10): 1587-93
27. Wildner M, Clark DE. Hip fracture incidence in East and West Germany: reassessment ten years after unification. Osteoporos Int 2001; 12 (2): 136-9
28. Melton 3rd LJ, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999; 9 (1): 29-37
29. O'Neill TW, Cooper C, Finn JD, et al. Incidence of distal forearm fracture in British men and women. Osteoporos Int 2001; 12 (7): 555-8
30. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87 (4): 1586-92
31. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85 (1): 231-6
32. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112 (4): 281-9
33. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23 (4): 508-16
34. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004; 7 (3): 255-61
35. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001; 20 (21): 3175-88
36. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004; 19 (2): 330-7
37. van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 2002; 13 (8): 624-9
38. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15 (4): 721-39
39. Meyer HE, Tverdal A, Falch JA, et al. Factors associated with mortality after hip fracture. Osteoporos Int 2000; 11 (3): 228-32
40. Forsen L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999; 10 (1): 73-8
41. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11 (7): 556-61
42. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003; 32 (5): 468-73
43. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004; 15 (2): 108-12
44. Statistisches Bundesamt. Statistical yearbook 2004 [in German]. Wiesbaden: Statistisches Bundesamt, 2004
45. Rote Liste Service GmbH. Red List 2004 catalogue of drugs [in German]. Frankfurt am Main: ECV Edictic Cantor Verlag, 2004
46. Verband deutscher Rentenversicherungsträger (VDR). Statistics on rehabilitations 1999 [in German]. Frankfurt am Main: VDR, 2000
47. Sozialgesetzbuch XI (SGB XI), section 43. Munich: Deutscher Taschenbuch Verlag, 2007
48. Sozialgesetzbuch XI (SGB XI), section 36. Munich: Deutscher Taschenbuch Verlag, 2007
49. Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004; 15 (1): 20-6
50. Stark R, Reitmeir P, König HH, et al. IBD: indirect costs of illness and quality of life in Germany [abstract]. Value Health 2005; 8 (6): A121
51. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350 (12): 1189-99
52. Tosteson AN, Jonsson B, Grima DT, et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 2001; 12 (10): 849-57
53. Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 2006; 17 (1): 29-40
54. Zethraeus N, Ben Sedrine W, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 2002; 13 (11): 841-57
55. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355-71
56. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-64
57. Claxton K, Cohen JT, Neumann PJ. When is evidence sufficient? Health Aff 2005; 24: 93-101
58. Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9 (22): 1-160
59. Schousboe JT, Nyman JA, Kane RL, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005; 142 (9): 734-41